The aim of this study was to assess the effectiveness of topiramate (TPM) as an add-on regimen in reducing seizure rate in a population sample of patients diagnosed with severe myoclonic epilepsy in infancy (SME). Eighteen patients were evaluated. The mean observation time was 10.5 months (range, 6-18 months). Seizure frequency and type were recorded. Topiramate was administered as an add-on regimen at a starting dose of 1 mg kg −1 and titrated to a maximum of 6-8 mg per kg per day. Different escalation rates were used, mainly weekly or fortnightly increments of dose. Three patients (16.6%) became seizure free, and 10 (55.6%) had a >50% reduction in seizure frequency: six of them (22.2%) achieved a reduction greater than 75%. Side-effects were observed in nine patients, eight with a weekly titration schedule and one with a fortnightly schedule. TPM is effective as adjunctive therapy for SME. Side-effects were mild and transient, generally related to rapid dosage titration.
INTRODUCTION
Severe myoclonic epilepsy in infancy (SME) is a rare epileptic syndrome first defined by Dravet et al. in 1982 1 and included as a syndrome in the International Classification of Epilepsy and Epileptic Syndromes (ICE) in 1989 under the heading of epileptic syndromes undetermined as to whether they are focal or generalized 2 . This type of epilepsy is very resistant to all forms of treatment including steroids. A transient response was observed with intravenous immunoglobulin (IVIG) therapy 3 . Topiramate (TPM) is a new antiepileptic drug with multiple mechanisms of action and a broad therapeutic spectrum [4] [5] [6] . Data from a recent meta-analysis suggested that TPM was possibly one of the most potent new drugs 7 . Indeed, TPM is effective in the treatment of partial refractory epilepsies [8] [9] [10] , and in severe epileptic syndromes such as Lennox-Gastaut syndrome 11, 12 and Infantile Spasms 13 . We report our observations of TPM therapy in a group of patients with SME refractory to various treatments.
MATERIALS AND METHODS
From October 1984 to October 1998 we collected 18 patients. The group of patients included eight males and 10 females with ages ranging from 2 to 22 years (mean age, 13.3 years) diagnosed with SME according to the following criteria 14 : (1) no past medical history, (2) seizure onset in the first year of life, usually as atypical febrile convulsions, or generalized clonic seizures, (3) myoclonic, and/or partial and/or atypical absence seizures between 2 and 4 years of age, (4) a normal interictal EEG at the beginning, (5) EEG recordings within the second year of life showing interictal generalized spike-and-wave complexes and/or photosensitive generalized polyspikes. Focal background anomalies may be present as well, and (6) normal initial psychomotor development which became delayed from the second year. Family history of epilepsy or refractoriness to anticonvulsant therapy also contributes to the diagnosis. Diagnosis was made retrospectively in seven patients and prospectively in 11.
All patients were considered refractory having been treated with a mean of 6.7 AEDs (range, [3] [4] [5] [6] [7] [8] . Eight patients were treated with IVIG and the other two with adrenocorticotropic hormone (ACTH). All patients were in pharmacological treatment at the time of the study with one or several antiepileptic drugs (AEDs) (median, 2.2 AEDs). Three patients were on single-drug therapy, nine on double therapy, five on triple therapy, and one received four drugs. During a 3-month period this treatment was unchanged and seizure frequency and type were recorded. Treatment was optimized when TPM was initiated. Demographics and clinical situation prior to TPM are shown in Table 1 . Three types of titration schedules were performed. In five cases the schedule was started with 0.5-1 mg kg −1 , and the dose was doubled every week. In four cases a starting dose of 1 mg kg −1 was followed by weekly increments of 1 mg kg −1 . In nine cases the schedule was started with 1 mg kg −1 and increased by 1 mg kg −1 every 2 weeks for 12 weeks. The maximum dosage in all cases was 6-8 mg kg −1 . Seizure rate and types, adverse effects and EEG findings were noted during the titration stage and the subsequent follow-up ranging from 6 to 18 months (mean, 10.5 months). Assessment of efficacy is essentially based on a reduction in seizure rate greater than 50%, but seizure suppression and reductions greater than 75% were separate for the analysis.
RESULTS
Before treatment eight patients presented only one type of seizure, 10 had two types and one patient had four seizure types. Generalized tonic-clonic seizures were the most frequent type being present in 15 patients, eight patients had partial seizures (mainly partial motor seizures), five patients had atypical absences and three patients had myoclonic seizures. Seizure frequency varied between 1 and 32 per month. Table 2 specifies seizure type, number, and EEG find- ings in every case. When topiramate was added, 14 patients were on valproate, three on monotherapy. At the end of the study, 72% of patients reached a >50% reduction in seizure rate, 50% had a reduction rate >75% and 16.6% were seizure free. Table 3 shows results during TPM therapy. All these patients started to improve from the titration period. Figure 1 presents response rate by seizure type. Response was slightly better in partial than in generalized seizures. The most dramatic response was with atypical absence seizures in which a total response rate was achieved. A better response rate was observed if the patient had one type of seizure or a combination of partial or generalized with atypical absence seizures. Response to TPM has no apparent relationship with the titration schedule, the maximal dose or time since diagnosis.
Adverse effects were observed mainly during the fourth and sixth weeks of treatment. Usually these were minor and lasted 10-14 days except for weight loss, which persisted longer. These occurred in most cases with a weekly increase and exceptionally when the dose was increased every fortnight. In no case was TPM withdrawn. 
DISCUSSION
Virtually all AEDs have been used in the treatment of SME usually with no clear results. Generally, valproic acid (VPA) is considered to be the most effective, though its actual efficacy has not been confirmed. Among newer AEDs, vigabatrin increased myoclonic seizures and lamotrigine has no significant effects, though it has been reported that it can increase seizures 15 . The use of IVIG at 100-200 mg kg −1 every 15 days to a total of six doses substantially improved the outcome of seizures in 30% of cases 3 . Improvement after puberty has been described 16 but not found in our series. Topiramate is the first oral AED that achieved a significant reduction in the number of seizures. Burkart et al. 17 reported 10% of patients becoming seizure free and 60% of patients showing a 50% reduction in seizure rate. These results were slightly worse than ours (16% and 72%, respectively). Improvement was evident during dose escalation in 30% of the cases and in the stabilization stage in the rest. Adverse effects were moderate and transient. This retrospective study suggests that TPM may be effective in the treatment of SME in infancy and has a specific role in the management of this epilepsy syndrome.
